This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
Good morning! This is a magical time of the year in Boston, with trees in full bloom. I want to hear from you! Send me email at BiotechScorecard@statnews.
Where art thou, lupus patients?
This week, Cullinan Oncology, now known as Cullinan Therapeutics, became the latest company to pivot from cancer to autoimmune disease. It joins Crispr Therapeutics, Cabaletta Bio, Nkarta, Caribou Biosciences, Allogene Therapeutics, Gracell (AstraZeneca), Bristol Myers Squibb, Fate Therapeutics, Eliem Therapeutics/Tenet Medicines, and Century Therapeutics/Clade Therapeutics in making the same shift, either partially or completely.
Click this link for the original source of this article.
Author: Adam Feuerstein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.